# Penumbra Inc (PEN) — merger/definitive [pending]
Source: SEC API (secapi.ai) · situation sit_fe728cad174ab3525d75 · retrieved 2026-08-11T16:14:36.168Z

## Overview
Penumbra Inc. develops innovative medical technologies to treat patients with serious conditions such as stroke, blood clots, and aneurysms.

Penumbra, Inc. entered into a definitive agreement to be acquired by Boston Scientific Corporation on January 15, 2026. Penumbra shareholders will receive $374 per share in a mix of cash and Boston Scientific stock. The transaction is expected to close in 2026, subject to receipt of Penumbra shareholder approval and required regulatory approvals and other customary closing conditions. Upon closing, Penumbra will become a standalone group within Boston Scientific, and Penumbra CEO Adam Elsesser will become a member of the Boston Scientific Board of Directors.

## Terms
- Counterparty: Boston Scientific Corporation · Consideration: mixed · Price/share: $374

## Key dates
- Announced 2026-01-15 · Expected close 2026-12-31

## Timeline
- 2026-01-15 · 425 (0000950103-26-000558): 425 - Penumbra Inc — *Penumbra Inc. develops innovative medical technologies to treat patients with serious conditions such as stroke, blood clots, and aneurysms.* Penumbra, Inc. entered into a definitive agreement to be acquired by Boston Scientific Corporation on January 15, 2026. Penumbra shareholders will receive $374 per share in a mix of cash and Boston Scientific stock. The transaction is expected to close in 2026, subject to receipt of Penumbra shareholder approval and required regulatory approvals and other customary closing conditions. Upon closing, Penumbra will become a standalone group within Boston Scientific, and Penumbra CEO Adam Elsesser will become a member of the Boston Scientific Board of Directors.
  https://www.sec.gov/Archives/edgar/data/1321732/0000950103-26-000558.txt
- 2026-01-15 · 425 (0000950103-26-000524): 425 - Penumbra Inc — *Penumbra Inc. is a medical device company that develops and manufactures minimally invasive surgical devices and systems for neurovascular and other medical applications.* On January 14, 2026, Penumbra, Inc. entered into a merger agreement with Boston Scientific Corporation and its subsidiary Pinehurst Merger Sub, Inc., whereby Merger Sub will merge into Penumbra, with Penumbra surviving as a wholly owned subsidiary of Boston Scientific. Each Penumbra share will be converted into either (i) $374.00 in cash, (ii) 3.8721 shares of Boston Scientific common stock, or (iii) a mix of cash and stock, subject to proration such that 73.26% of shares receive cash consideration and 26.74% receive stock consideration. Based on 39,229,670 shares outstanding as of January 12, 2026, the transaction is valued at approximately $14.7 billion in aggregate consideration.
  https://www.sec.gov/Archives/edgar/data/1321732/0000950103-26-000524.txt

## Citations
- 0000950103-26-000558 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000095010326000558
- 0000950103-26-000524 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000095010326000524